Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AEE788 · 3 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| AEE788 + non EIACD | EXPERIMENTAL | - |
| AEE788 + EIACD | EXPERIMENTAL | - |
| AEE788 200 mg + RAD001 5 mg | EXPERIMENTAL | AEE788 200 mg qd, RAD001 5 mg qd |
| AEE788 150 mg + RAD001 5mg | EXPERIMENTAL | AEE788 150 mg qd, RAD001 5 mg qod |
| 1 | EXPERIMENTAL | Continuous daily dosing |
| 2 | EXPERIMENTAL | Monday, Wednesday, Friday Dosing |
| Name | Type | Description |
|---|---|---|
| AEE788 | DRUG | - |
| everolimus | DRUG | Everolimus was formulated as tablets of 2.5 mg and 5 mg strength and supplied in blister packs. |
Inclusion Criteria: * Histologically confirmed GBM in first or second recurrence or relapse * Adequate hematologic, hepatic and renal function * Age ≥ 18 years * Karnofsky performance status score ≥ 70% * Life expectancy ≥ 12 weeks Exclusion Criteria: * Peripheral neuropathy \> grade 1 * Diarrhea...
AEE788 is an investigational small molecule being studied for the treatment of brain and central nervous system tumors, glioblastoma multiforme, and advanced cancer. It was evaluated in Phase 1 clinical trials in patients with recurrent or relapsed glioblastoma multiforme and in adults with advanced cancer.
AEE788 is being developed by Novartis AG, which trades under the ticker symbol NVS. The company sponsored Phase 1 clinical trials of the drug in the United States.
AEE788 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. All three clinical trials of AEE788 have been completed, and no trials are currently active.
AEE788 has been studied in three completed Phase 1 trials: NCT00107237, which tested AEE788 with everolimus in recurrent or relapsed glioblastoma multiforme; NCT00116376, which tested AEE788 alone in recurrent or relapsed glioblastoma multiforme; and NCT00118456, which tested oral AEE788 in adults with advanced cancer.
AEE788 is a small molecule that targets receptor tyrosine kinases involved in tumor growth and angiogenesis. By inhibiting these kinases, it is designed to block signaling pathways that promote cancer cell proliferation and survival.